BRPI0511768A - composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto - Google Patents

composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto

Info

Publication number
BRPI0511768A
BRPI0511768A BRPI0511768-2A BRPI0511768A BRPI0511768A BR PI0511768 A BRPI0511768 A BR PI0511768A BR PI0511768 A BRPI0511768 A BR PI0511768A BR PI0511768 A BRPI0511768 A BR PI0511768A
Authority
BR
Brazil
Prior art keywords
compound
optionally substituted
prodrug
prophylaxis
cancer
Prior art date
Application number
BRPI0511768-2A
Other languages
English (en)
Inventor
Tomoyasu Ishikawa
Takahiko Taniguchi
Hiroshi Banno
Masaki Seto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of BRPI0511768A publication Critical patent/BRPI0511768A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems

Abstract

COMPOSTO, PRó-DROGA, MéTODOS PARA A PRODUçãO DE UM COMPOSTO, PARA A PROFILAXIA OU TRATAMENTO DE CáNCER EM UM MAMìFERO, AGENTE FARMACêUTICO, E, USO DE UM COMPOSTO A presente invenção diz respeito a um composto representado pela fórmula: em que W é C(R¬ ¹¬) ou N, cada A é um grupo arila opcionalmente substituído ou um grupo heteroarila, X¬ ¹¬ é -NR¬ ³¬-Y~ ¹¬m-, -O-, -S-, -SO-, -SO~ 2~- ou -CHR¬ ³¬- em que R¬ ³¬ é um átomo de hidrogênio ou um grupo hidrocarboneto alifático opcionalmente substituído, ou R¬ ³¬ é opcionalmente ligado a A para formar uma estrutura de anel opcionalmente substituído, R¬ ¹¬ é um átomo de hidrogênio ou um grupo opcionalmente substituído ligado por intermédio de um átomo de carbono, um átomo de nitrogênio ou um átomo de oxigênio, R¬ ²¬ é um átomo de hidrogênio ou grupo opcionalmente substituído ligado por intermédio de um átomo de carbono ou um átomo de enxofre, ou e R¬ ¹¬ e R¬ ²¬, ou R~ ²¬ e R¬ ³¬ são opcionalmente ligados para formar uma estrutura de anel opcionalmente substituído, ou um sal deste e um inibidor da tirosina quinase ou um agente para a profilaxia ou tratamento de câncer, que contenha este composto ou uma pró-droga deste.
BRPI0511768-2A 2004-06-02 2005-06-01 composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto BRPI0511768A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004165050 2004-06-02
JP2005058231 2005-03-02
PCT/JP2005/010451 WO2005118588A1 (ja) 2004-06-02 2005-06-01 縮合複素環化合物

Publications (1)

Publication Number Publication Date
BRPI0511768A true BRPI0511768A (pt) 2008-01-08

Family

ID=35462874

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511768-2A BRPI0511768A (pt) 2004-06-02 2005-06-01 composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto

Country Status (18)

Country Link
US (4) US7507740B2 (pt)
EP (1) EP1752457B1 (pt)
JP (2) JP4134227B2 (pt)
KR (1) KR101194622B1 (pt)
AU (1) AU2005250285B2 (pt)
BR (1) BRPI0511768A (pt)
CA (1) CA2569016C (pt)
CR (1) CR8827A (pt)
GE (1) GEP20105024B (pt)
IL (1) IL179414A (pt)
MA (1) MA28973B1 (pt)
ME (1) MEP8409A (pt)
MX (1) MXPA06013996A (pt)
NO (1) NO20066015L (pt)
NZ (1) NZ551938A (pt)
RU (1) RU2389731C2 (pt)
TW (1) TWI392679B (pt)
WO (1) WO2005118588A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
CA2615946A1 (en) * 2005-07-22 2007-02-01 Sunesis Pharmaceuticals, Inc. Pyrazolo pyrimidines useful as aurora kinase inhibitors
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
US20100008912A1 (en) 2006-10-06 2010-01-14 Takeda Pharmaceutical Company Limited Combination drug
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
CA2682504C (en) * 2007-04-05 2012-10-30 Amgen Inc. Aurora kinase modulators and method of use
EP2155689B1 (en) * 2007-05-31 2015-07-08 Boehringer Ingelheim International GmbH Ccr2 receptor antagonists and uses thereof
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
UY31684A (es) 2008-03-03 2009-11-10 Takeda Pharmaceutical Farmaco combinado
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
JP2011515401A (ja) 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
WO2010036928A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with lkb1 non-expression (deletion or mutation)
WO2010036910A1 (en) * 2008-09-26 2010-04-01 Yoshikazu Ohta Heart protection by administering an amp-activated protein kinase activator
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
MA33085B1 (fr) 2008-12-19 2012-03-01 Boehringer Ingelheim Int Pyrimidine-4 carboxamides cycliques en tant qu'antagonistes du recepteur ccr2 pour le traitement d'inflammations, de l'asthme et des broncho-pneumopathies chroniques obstructives
MX2011008058A (es) * 2009-01-30 2011-09-01 Takeda Pharmaceutical Compuesto de anillo fusionado y su uso.
EP2471793B1 (en) * 2009-08-26 2016-10-05 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011040212A1 (en) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Therapeutic agent for brain tumor
JP5632014B2 (ja) 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト及びこれらの使用
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
WO2011151251A1 (en) 2010-06-01 2011-12-08 Boehringer Ingelheim International Gmbh New ccr2 antagonists
CA2760174A1 (en) * 2011-12-01 2013-06-01 Pharmascience Inc. Protein kinase inhibitors and uses thereof
WO2012143144A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
WO2013010839A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Novel and selective ccr2 antagonists
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
KR20160036053A (ko) * 2013-07-31 2016-04-01 메르크 파텐트 게엠베하 Btk 저해제로서 피리딘, 피리미딘, 및 피라진, 및 이들의 용도
WO2015134539A1 (en) 2014-03-03 2015-09-11 The Regents Of The University Of California Mcl-1 antagonists
KR20160142401A (ko) 2014-04-25 2016-12-12 화이자 인코포레이티드 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
EA030603B1 (ru) 2014-05-01 2018-08-31 Новартис Аг СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ АГОНИСТОВ Toll-ПОДОБНОГО РЕЦЕПТОРА 7
NZ724878A (en) 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3591845B1 (en) * 2018-07-05 2023-08-09 Universite De Bretagne Sud Sorting device and method for elementary check node processing for message-passing decoding of non-binary codes
WO2020118183A1 (en) * 2018-12-06 2020-06-11 Kapoor Tarun M 2,4-diaminopyrimidine bicycles for treating cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS554116B2 (pt) * 1971-08-20 1980-01-29
KR100337720B1 (ko) * 1993-06-21 2002-11-02 메렐 파마슈티칼스 인크. 신규카보사이클릭뉴클레오사이드화합물
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
PL190489B1 (pl) * 1996-04-12 2005-12-30 Warner Lambert Co Nieodwracalne inhibitory kinaz tyrozyny, kompozycja farmaceutyczna je zawierająca i ich zastosowanie
TR199900048T2 (xx) * 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
JP4242928B2 (ja) * 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト 置換ピロロピリミジンおよびその製造方法
CA2217373A1 (en) 1996-10-10 1998-04-10 Michael John Martin Benzo¬b|thiophene compounds, intermediates, formulations, and methods
BR9713552A (pt) * 1996-11-27 2000-01-25 Pfizer Derivados de pirimidina bicìclicos condensados
ATE296825T1 (de) 1997-08-05 2005-06-15 Pfizer Prod Inc 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
ES2219033T3 (es) * 1998-07-22 2004-11-16 Daiichi Suntory Pharma Co., Ltd. Inhibidores de nf-kappa b que contienen derivados de indano como ingrediente activo.
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
AU7323000A (en) * 1999-08-26 2001-04-10 Plant Research International B.V. Conditional inhibition of vegetative propagation
RU2003134646A (ru) 2001-04-30 2005-04-20 Глэксо Груп Лимитед (GB) Конденсированные пиримидины в качестве антагонистов кортикотропинвысокобождающего фактора (crf)
CN1649848A (zh) 2001-04-30 2005-08-03 葛兰素集团有限公司 作为促肾上腺皮质激素释放因子(crf)拮抗剂的稠合嘧啶衍生物
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
JP2003183283A (ja) * 2001-12-18 2003-07-03 Takeda Chem Ind Ltd 縮合インドール化合物、その製造法および用途
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
EP1636195A1 (en) * 2003-05-27 2006-03-22 Pfizer Products Inc. Quinazolines and pyrido[3,4-d]pyrimidines as receptor tyrosine kinase inhibitors
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
JP2006020985A (ja) 2004-07-05 2006-01-26 Kiyoshi Owada 微小孔を用いた入浴剤用炭酸ガス拡散装置
JP5096142B2 (ja) * 2004-07-30 2012-12-12 メチルジーン インコーポレイテッド Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
ES2473341T3 (es) * 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
US20100008912A1 (en) * 2006-10-06 2010-01-14 Takeda Pharmaceutical Company Limited Combination drug
US20100183604A1 (en) * 2007-06-19 2010-07-22 Takeda Pharmaceutical Company Limited Preventive/remedy for cancer
PE20091580A1 (es) * 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado

Also Published As

Publication number Publication date
NZ551938A (en) 2010-07-30
US20090203717A1 (en) 2009-08-13
TW200611907A (en) 2006-04-16
JP2008247907A (ja) 2008-10-16
MXPA06013996A (es) 2007-02-08
US20090018335A1 (en) 2009-01-15
EP1752457B1 (en) 2014-03-19
AU2005250285A1 (en) 2005-12-15
KR20070026695A (ko) 2007-03-08
NO20066015L (no) 2007-02-13
JP4937172B2 (ja) 2012-05-23
TWI392679B (zh) 2013-04-11
MEP8409A (en) 2011-12-20
CA2569016A1 (en) 2005-12-15
KR101194622B1 (ko) 2012-10-29
JPWO2005118588A1 (ja) 2008-04-03
US20090029973A1 (en) 2009-01-29
CA2569016C (en) 2012-11-27
US8178543B2 (en) 2012-05-15
AU2005250285B2 (en) 2011-08-18
RU2006147267A (ru) 2008-07-20
JP4134227B2 (ja) 2008-08-20
RU2389731C2 (ru) 2010-05-20
WO2005118588A1 (ja) 2005-12-15
US7507740B2 (en) 2009-03-24
EP1752457A1 (en) 2007-02-14
US20070244132A1 (en) 2007-10-18
GEP20105024B (en) 2010-06-25
EP1752457A4 (en) 2010-05-26
IL179414A (en) 2013-11-28
IL179414A0 (en) 2007-05-15
CR8827A (es) 2007-04-20
MA28973B1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
BRPI0511768A (pt) composto, pró-droga, métodos para a produção de um composto, e para a profilaxia ou tratamento de cáncer em um mamìfero, agente farmacêutico, e, uso de um composto
ECSP10010356A (es) Derivados de carboxamidas n-azabicíclicas, su preparación y su aplicación en terapéutica
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
JO2644B1 (en) Derivatives of N- (amino-aryl mixture) -H1- indole-2-carboxamide Synthesis and therapeutic use
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
BR122019003178B1 (pt) método de controle de pestes
BRPI0510305A (pt) composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
BRPI0514644A (pt) composto fosforamidita, composto ácido ribonucléico, e método para produzir oligo-rna
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
MX2007015863A (es) Inhibidores de esfingosina cinasa.
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
WO2006136837A3 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
MY145932A (en) N-(heteroaryl)-1h-indole-2-carboxamide derivatives, preparation thereof and therapeutic application thereof
NI200800015A (es) Derivados de n-(heteroaril)-1-heteroarilalquil - 1h - indol - 2 - carboxamidas, su preparación y su aplicación en terapéutica.
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
UA101668C2 (ru) Производные азакарболинов, способ их получения и применения в терапии
SE0403171D0 (sv) New compounds

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.